Thromboelastography parameters in chronic viral liver disease and liver resection: a retrospective study by Ying Di, Jialu Li, Chunjuan Ye, Zheng Wang, Qianqian Zhu

“…Child–Turcotte–Pugh (CTP) and model for end-stage liver disease (MELD) scores were used to categorise stages of liver cirrhosis. Liver resections were classified as low, medium and high complexity. …”
Get full text

Psychometric Validation of the Hepatitis C Symptom and Impact Questionnaire (HCV-SIQv4) in a Diverse Sample of Adults with Chronic Hepatitis C Virus Infection Treated with an Inter... by Andrew Trigg, Eric Chan, Helen Kitchen, Tom Willgoss, Kai Fai Ho, Renee Pierson, Jane Scott

“…Greater symptom severity and worse impact scores were associated with liver cirrhosis, depression, severe fatigue and health limitations. …”
Get full text

Antiphospholipid Syndrome as a Cause of Recurrent Portal Vein Thrombosis in a Man with a Medical History of other Thrombosis by R. G. Sayfutdinov, R. R. Saifutdinov, R. R. Akhunova, T. V. Saifutdinova, G. R. Absalyamova, T. V. Dvoryankina, G. R. Akhunova

“…For several years, the patient had the diagnosis of cirrhosis based on the presence of signs of portal hypertension. …”
Get full text

Rare forms of nonalcoholic fatty liver disease: hereditary lysosomal acid lipase deficiency by M. V. Mayevskaya, V. T. Ivashkin, M. S. Zharkova, T. P. Nekrasova, G. I. Ayusheva, R. V. Maslennikov

“…Early detection of DLAL patients and adequate treatment can prevent development of the liver cirrhosis associated to this disease, as well as cardio-vascular complications.…”
Get full text

Infusion therapy for chronic liver diseases by I. A. Kurkina, M. V. Mayevskaya, I. N. Tikhonov, V. N. Zozulya, V. I. Leschenko

“…Application of basic group infusion solutions along with complex anti-hypoxia agents helps to correct water and electrolyte imbalance as well as disorders of acid-base state, carry out body detoxication, normalize blood pressure, treat edema and ascites syndrome, protein-energy malnutrition, prevent renal value and other complications in liver cirrhosis patients. Comprehensive treatment of liver diseases includes application of modern infusion agents (anti-hypoxia/anti-oxidation) containing pharmacologically active metabolic substances that include succinate-containing drugs developed on the basis of succinic acid and its salts. …”
Get full text

Economic Evaluation of Boceprevir for the Treatment of Patients with Genotype 1 Chronic Hepatitis C Virus Infection in Hungary by Raymond Odhiambo, Jagpreet Chhatwal, Shannon Allen Ferrante, Antoine El Khoury, Elamin Elbasha

“…Model states were fibrosis (F0–F4, defined using METAVIR fibrosis scores), decompensated cirrhosis (DC), hepatocellular carcinoma (HCC), liver transplantation (LT), and liver-related deaths (LD). …”
Get full text

Biliary atresia: The profile, management and outcome of patients treated at a tertiary hospital in central South Africa by E Brits, S M le Grange

“…Without intervention, the disease rapidly progresses to liver cirrhosis and fibrosis, with end-stage liver failure and death occurring within the first 3 years of life. …”
Get full text

Patient Management in Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus by A. E. Bagriy, A. D. Zubov, M. V. Khomenko, E. S. Mikhailichenko, E. A. Pylaeva, N. A. Khaustova, E. V. Bryukhovetskaya

“…NAFLD is associated with an increased cardiovascular risk (due to association with “metabolic syndrome”) and the risks of liver cirrhosis and hepatocellular carcinoma. Macro- and microvascular complications in T2D comorbidity entail a higher overall mortality. …”
Get full text

Histological diagnosis of primary biliary cholangitis in one patient without cholestasis alterations: a case report that escaped guidelines by Matteo Biagi, Elisa Bernasconi, Carmela Cursaro, Enrico Ronconi, Filippo Zanni, Pamela Sighinolfi, Pietro Andreone

“…Primary biliary cholangitis (PBC) is an autoimmune cholangiopathy that affects mainly women and, if untreated, can evolve into biliary cirrhosis. Its prevalence varies worldwide, depending on race, and accounts for 22.27 cases/100,000 habitants in Europe. …”
Get full text

Cirrhotic cardiomyopathy by S. N. Mammayev, A. M. Karimova, T. E. Il’yasova, A. Sh. Khasayev

“…To define cirrhotic cardiomyopathy (CCM), to reveal its pathogenic mechanisms, features of clinical manifestations, to reflect main therapeutic approaches, effect of orthotopic transplantation of liver (OTL) and transjugular portosystemic shunting (TIPS) on the course and prognosis of cardio-vascular disorders at liver cirrhosis (LC).Original positions. Disorder of signal conduction from β-adrenoreceptors, calcium channels receptors, decrease of cardiomyocyte membrane fluidity, increase of nitric oxide and carbon monoxide synthesis, elevation of endocannabinoid system activity and many other changes observed at LC, cause development of complex of structural and functional disorders in myocardium, underlying development of CCM. …”
Get full text

Evaluation of Small Intestinal Permeability in Patients with Overlap Syndrome (Autoimmune Hepatitis/Primary Biliary Cholangitis) by D. R. Akberova, A. Kh. Odintcova, D. I. Abdulganieva

“…An increased small intestinal permeability was revealed: hepatitis stage — 0.19 [0.13; 0.30] (p < 0.001), liver cirrhosis stage — 0.18 [0.09; 0.30] (p < 0.05) compared with the control group. …”
Get full text

Co-dynamics of hepatitis B and C viruses under the influence of CTL immunity by A.M. Elaiw, GH.S. Alsaadi, A.A. Raezah, A.D. Hobiny

“…Understanding the cytotoxic T lymphocyte (CTL) immune response against hepatitis B virus (HBV) and hepatitis C virus (HCV) infections is crucial, as these infections can lead to liver cirrhosis and cancer. Mathematical models provide valuable support for biological and medical research by helping to understand the within-host dynamics of single or multiple viral infections and by aiding the development of effective drug therapies. …”
Get full text

Timosin alpha-1 immunomodulating properties by M. V. Mayevskaya

“…Timosin alpha-1 can be applied at immune antineoplastic therapy, in particular in treatment of hepatocellular carcinoma which is related to a final stage of persistent infection of hepatitis B and C viruses, that, as a rule, develops on a background of liver cirrhosis and in Caucasian patients.Conclusion. Timosin alpha-1 is successfully applied in clinical practice in treatment of chronic viral hepatites B and C, as antineoplastic immunomodulating drug and requires further active studies.…”
Get full text

Chronic hepatitis B and risk of kidney involvement by M. V. Mayevskaya, I. N. Tikhonov, V. T. Ivashkin

“…At development of liver cirrhosis (LC) and its decompensation one more aspect of renal disease at CHB arises i.e. risk of hepatorenal syndrome (HRS) of the 1st or 2nd type that is a poor prognostic marker and requires individual therapeutic approach.Conclusion. …”
Get full text

Collagen fibers quantification for liver fibrosis assessment using linear dichroism photoacoustic microscopy by Yang Qiu, Honghui Li, Kun Yu, Jiali Chen, Li Qi, Yinghua Zhao, Liming Nie

“…Liver fibrosis represents a progressive pathological condition that can culminate in severe hepatic dysfunction, potentially advancing to cirrhosis and liver cancer. The extent of liver fibrosis is intrinsically associated with the quantity of collagen fibers. …”
Get full text

COVID-19 in Patients with Primary Biliary Cholangitis by М. К. Prashnova, K. L. Raikhelson, N. V. Marchenko, S. M. Zakharenko

“…Between March 2020 and March 2021, 50 patients (34.7 %) suffered COVID-19, with mean age of 58.8 ± 10.7 years, 16 of which were diagnosed with liver cirrhosis. Mild COVID-19 was observed in 34 (68 %) people, moderate course — in 14 (28 %), severe — in 2 (4 %), cases of extremely severe course were not recorded. 12 patients were hospitalized, 8 of which received oxygen therapy due to a decrease in SpO2 < 94 %, there was no need for the use of other methods of oxygen therapy in any case. …”
Get full text

Practical Aspects of Clinical Manifestations, Pathogenesis and Therapy of Alcoholic Liver Disease and Non-alcoholic Fatty Liver Disease: Expert Opinion by V. V. Tsukanov, M. F. Osipenko, E. V. Beloborodova, M. A. Livzan, I. B. Khlynov, S. A. Alekseenko, Yu. P. Sivolap, J. L. Tonkikh, A. V. Vasyutin

“…In the treatment of NAFLD, diet and lifestyle modification, weight loss, the use of insulin sensitizers, vitamin E, statins (in the presence of hyperlipidemia) and drugs with metabolic activity are effective.Currently, a point of view is being actively expressed about the synergism of the action of alcohol and the metabolic syndrome on the development of fibrosis, cirrhosis, and hepatocellular carcinoma. The current international consensus recommends a change in the nomenclature of NAFLD and ALD and proposes the terms “metabolically associated steatotic liver disease” and “metabolically associated alcoholic liver disease”.Conclusion. …”
Get full text

Challenges in Diagnosing Intrahepatic Cholangiolithiasis in a 39-Year-Old Patient by A. K. Guseva, O. N. Sergeyeva, T. P. Nekrasova, O. T. Imaraliev, A. V. Okhlobystin, Y. N. Shirokova, A. S. Ostrovskaya, M. S. Zharkova, A. S. Cherenda, V. T. Ivashkin

“…Primary sclerosing cholangitis is a chronic progressive liver disease characterized by destructive inflammation and fibrosis in the bile ducts, leading to biliary strictures, secondary biliary cirrhosis, portal hypertension and liver failure. Cholangiolithiasis occurs in more than half of cases of primary sclerosing cholangitis and can be both a complication and a cause of secondary sclerosing cholangitis, maintaining inflammation in the ducts and facilitating stone formation. …”
Get full text

Polymorphism of renin — angiotensin system genes in progression of liver fibrosis in patients with chronic hepatitis C by O. V. Taratina, T. N. Krasnova, L. M. Samokhodskaya, T. N. Lopatkina, V. A. Tkachuk, N. A. Mukhin

“…Overall 109 patients with CHC and liver cirrhosis C with established stage of fibrosis and duration of disease have been divided into group of «rapidly progressing fibrosis» (55 patients, ≥0,130 fibrosis points/year) and «slowly progressing fibrosis» (54 persons, <0,130 fibrosis units/year). …”
Get full text

Epidemiologic features of non-alcoholic fatty liver disease in Russia by O. M. Drapkina, V. T. Ivashkin

“…The prevalence of NAFLD among adult population of the Russian Federation was 27%, including 80,3% of hepatic steatosis cases, 16,8% — nonalcoholic steatohepatitis and 2,9% — liver cirrhosis. Frequency of NAFLD detection increase by the age of 50. …”
Get full text